The model is now part of the attack surface. This page covers what reviewers expect on SBOM and AI-BOM, the six model-layer threats you must enumerate, and the controls that map cleanly to FDA's Feb 2026 cyber guidance, IMDRF, and EU AI Act Article 15.
FDA's Feb 2026 cybersecurity guidance now treats AI/ML models as a first-class attack surface. Submissions are expected to enumerate threats against the model itself · not just the network around it · and to map controls back to IEC 81001-5-1 and the SPDF.
FDA Feb 2026 cyber · IEC 81001-5-1 · IMDRF/CYBER WG/N60
SBOM and AI-BOM
An SBOM lists software components. An AI-BOM extends that to weights, training datasets, base models, tokenizers, and inference dependencies. Reviewers increasingly ask for both, with provenance, license, and known-vulnerability status for every line.
FDA Feb 2026 cyber §IV.B · CycloneDX 1.6 · SPDX 3.0 AI profile
Model-layer threats
Poisoning, evasion, extraction, inversion, and prompt injection are no longer research curiosities. EU AI Act Article 15 explicitly names accuracy, robustness, and cybersecurity together · meaning a robustness gap is now also a cyber gap.
EU AI Act Art. 15 · NIST AI 100-2 · OWASP LLM Top 10
SBOM + AI-BOM
Two bills of materials · one device.
Reviewers no longer accept a software-only SBOM for an AI/ML device. The AI-BOM extends coverage to the model itself · weights, training data, base models, tokenizers · with provenance, license, and known-vulnerability status for every line.
CycloneDX 1.6 · SPDX 3.0 AI profile · IMDRF/CYBER WG/N60
CVE / GHSA / model-card advisories, with severity and exploitability.
Model-layer threats
The six reviewers now expect to see enumerated.
Each of these belongs in your premarket threat register with a scenario, mitigation, and citation. The threat model builder generates a STRIDE-mapped register tailored to your model type and deployment.
Training-data poisoning
Scenario · Adversary injects mislabeled or backdoored samples so the deployed model misclassifies a targeted input class · often silently and only at inference time.
Control · Dataset provenance log, hash-anchored snapshots, statistical outlier detection on retraining batches, signed dataset releases.
Adversarial evasion
Scenario · Crafted input perturbations cause the model to flip its prediction without a clinician noticing the input is anomalous.
Control · PGD / AutoAttack in V&V, input plausibility gates, confidence-calibrated rejection, periodic red-team round.
Model extraction & inversion
Scenario · Query-based attacks reconstruct decision boundaries, recover protected attributes, or infer membership of a specific patient record in the training set.
Control · Per-tenant query rate limits, anomaly detection on query distribution, output coarsening, differential-privacy training where feasible.
Prompt injection (LLM / foundation)
Scenario · User-supplied or upstream-document content overrides the system prompt, exfiltrating data or triggering off-label clinical advice.
Control · Strict input/output channel separation, allowlisted tools, output classifier, refusal eval suite, no tool execution on untrusted strings.
Weight / artifact tampering
Scenario · Model weights, tokenizer, or post-processing code are modified in storage or transit, producing silent behaviour drift after deployment.
Control · Sigstore / cosign signatures on model artifacts, integrity check at load time, immutable artifact registry, AI-BOM coverage of weights.
Upstream foundation-model drift
Scenario · Third-party foundation provider silently retrains or deprecates the base model, breaking the locked behaviour assumed in the submission.
Control · Pin model version + provider SLA, regression eval gate, fallback to last-validated snapshot, supplier change-notification clause.
Submission-ready checklist
Eight items that close the cyber gap.
Threat model covers STRIDE for the software and the AI-specific six (poisoning, evasion, extraction, inversion, prompt injection, weight tampering).
SBOM in CycloneDX 1.6 or SPDX 3.0, machine-readable, regenerated on every release.
AI-BOM lists weights, training data snapshot, base model version, tokenizer, embeddings · with hashes and licenses.
Model artifacts signed (Sigstore / cosign) and integrity-verified at load time.
Inference endpoint behind mutual TLS or OIDC, per-identity quotas, billing alarms on cost-amplification.
Append-only inference log: input hash, model version, weights digest, output, confidence, clinician ID · retained per local law.
Drift monitoring tied to PCCP thresholds, with automatic field safety escalation if breached.
Coordinated vulnerability disclosure policy published, with a 90-day patch SLA for critical model-layer issues.
FAQ
The questions reviewers and sponsors ask.
Is an SBOM enough, or do I really need an AI-BOM?+
An SBOM alone no longer satisfies reviewers for AI/ML-enabled devices. FDA's Feb 2026 cybersecurity guidance, plus IMDRF CYBER WG/N60, expect coverage of model weights, training-data provenance, base-model versions, tokenizers, and inference dependencies · which is what an AI-BOM (CycloneDX 1.6 or SPDX 3.0 AI profile) adds.
Which model-layer threats must a 510(k) or De Novo submission enumerate?+
At minimum: training-data poisoning, adversarial evasion, model extraction, membership / attribute inference, weight or artifact tampering, and · for LLM / foundation models · prompt injection. Each should appear in the threat register with a scenario, mitigation, and citation to FDA Feb 2026 cyber, NIST AI 100-2, or EU AI Act Art. 15.
How does EU AI Act Article 15 interact with FDA cybersecurity guidance?+
Article 15 bundles accuracy, robustness, and cybersecurity into a single conformity requirement for high-risk AI systems. A robustness gap is therefore also a cybersecurity gap under EU law, and the same evidence (adversarial testing, drift monitoring, signed artifacts) can usually be re-used for an FDA submission with citation mapping.
Do upstream foundation-model changes need to be reported post-market?+
Yes. If you rely on a third-party foundation model, a silent retrain or deprecation by the provider can change clinical behaviour. Pin the version, get a change-notification clause in the supplier contract, and treat any provider-driven change as a PCCP-scoped modification with a regression eval gate before re-deployment.
Sponsor
Need this scoped against your device?
Blue Goat Cyber has run penetration testing, threat modeling, SBOM, and AI/ML model security on 250+ FDA submissions · zero rejections. They sponsor this page and the threat model builder.